{"entity":{"id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","aka":[],"tldr":"A phase 2 trial of BI 764532, dose 1 in small-cell lung cancer and neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.","summary":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 2 interventional study registered as NCT05882058 by Boehringer Ingelheim, with 204 participants planned, started 2023-10-13 and due to reach its primary completion in 2027-12-17. Interventions recorded: BI 764532, dose 1, BI 764532, dose 2 and Ventana DLL3 RxDx assay.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05882058","url":"https://clinicaltrials.gov/study/NCT05882058"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["boehringer-ingelheim"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05882058","phase":"2","setting":"DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas","sponsor":"Boehringer Ingelheim","enrolled":204,"outcomes":[]},"route":"/trials/nct05882058/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/"}]}}